Symbols / TEVA $31.61 -0.50% Teva Pharmaceutical Industries Limited

Healthcare • Drug Manufacturers - Specialty & Generic • Israel • NYQ
TEVA Chart
About

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders – chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Drug Manufacturers - Spe Market Cap 37.71B
Enterprise Value 50.02B Income 1.41B Sales 17.26B
Book/sh 6.88 Cash/sh 3.09 Dividend Yield —
Payout 0.00% Employees 31173 IPO —
P/E 26.12 Forward P/E 10.15 PEG —
P/S 2.19 P/B 4.60 P/C —
EV/EBITDA 10.10 EV/Sales 2.90 Quick Ratio 0.54
Current Ratio 1.04 Debt/Eq 217.72 LT Debt/Eq —
EPS (ttm) 1.21 EPS next Y 3.11 EPS Growth —
Revenue Growth 11.40% Earnings 2026-04-29 ROA 6.17%
ROE 20.79% ROIC — Gross Margin 51.79%
Oper. Margin 27.28% Profit Margin 8.17% Shs Outstand 1.16B
Shs Float 1.07B Short Float 2.34% Short Ratio 3.44
Short Interest — 52W High 37.35 52W Low 13.04
Beta 0.76 Avg Volume 7.94M Volume 2.76M
Target Price $38.18 Recom Strong_buy Prev Close $31.77
Price $31.61 Change -0.50%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$38.18
Mean price target
2. Current target
$31.61
Latest analyst target
3. DCF / Fair value
$31.40
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$31.61
Low
$28.00
High
$45.00
Mean
$38.18

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-09 main B of A Securities Buy → Buy $42
2026-03-04 reit Piper Sandler Overweight → Overweight $41
2026-02-18 main Truist Securities Buy → Buy $42
2026-02-09 main Goldman Sachs Buy → Buy $45
2026-01-30 main Barclays Overweight → Overweight $38
2026-01-29 main Scotiabank Sector Outperform → Sector Outperform $40
2026-01-29 main Truist Securities Buy → Buy $38
2026-01-06 main Jefferies Buy → Buy $40
2025-12-22 main Piper Sandler Overweight → Overweight $40
2025-12-19 main Goldman Sachs Buy → Buy $35
2025-12-16 main JP Morgan Overweight → Overweight $35
2025-12-09 main B of A Securities Buy → Buy $32
2025-12-09 init Barclays — → Overweight $35
2025-12-08 main Goldman Sachs Buy → Buy $31
2025-12-05 init Scotiabank — → Sector Outperform $35
2025-11-06 main JP Morgan Overweight → Overweight $28
2025-10-03 main JP Morgan Overweight → Overweight $26
2025-09-24 main UBS Buy → Buy $26
2025-06-26 main UBS Buy → Buy $23
2025-06-06 init Goldman Sachs — → Buy $24
News
RSS: Latest TEVA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-05 FRANCIS RICHARD D Chief Executive Officer — 20,025 $31.67 $634,160
2026-03-05 FRANCIS RICHARD D Chief Executive Officer — 42,452 — —
2026-03-05 SABAG MARK Officer — 15,723 — —
2026-03-05 KALIF ELIYAHU SHARON Chief Financial Officer — 19,916 — —
2026-03-05 HUGHES ERIC A Officer — 9,533 $31.67 $301,895
2026-03-05 HUGHES ERIC A Officer — 19,654 — —
2026-03-05 FOX CHRISTINE Officer — 7,924 $31.67 $250,940
2026-03-05 FOX CHRISTINE Officer — 17,819 — —
2026-03-05 SHIELDS MATTHEW Officer — 17,295 $31.67 $547,705
2026-03-05 SHIELDS MATTHEW Officer — 17,295 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
17,257.00
+4.31%
16,544.00
+4.41%
15,845.00
+6.16%
14,925.00
Operating Revenue
16,834.00
+6.55%
15,799.00
+3.43%
15,275.00
+5.37%
14,497.00
Cost Of Revenue
8,320.00
-1.90%
8,481.00
+3.43%
8,200.00
+3.12%
7,952.00
Reconciled Cost Of Revenue
8,320.00
-1.90%
8,481.00
+3.43%
8,200.00
+3.12%
7,952.00
Gross Profit
8,938.00
+10.84%
8,064.00
+5.48%
7,645.00
+9.64%
6,973.00
Operating Expense
4,986.00
+6.09%
4,700.00
+5.59%
4,451.00
+3.92%
4,283.00
Research And Development
1,013.00
+1.50%
998.00
+4.72%
953.00
+13.72%
838.00
Selling General And Administration
3,973.00
+7.32%
3,702.00
+5.83%
3,498.00
+1.54%
3,445.00
Selling And Marketing Expense
2,686.00
+5.71%
2,541.00
+8.78%
2,336.00
+3.13%
2,265.00
General And Administrative Expense
1,287.00
+10.85%
1,161.00
-0.09%
1,162.00
-1.53%
1,180.00
Other Gand A
1,287.00
+10.85%
1,161.00
-0.09%
1,162.00
-1.53%
1,180.00
Total Expenses
13,306.00
+0.95%
13,181.00
+4.19%
12,651.00
+3.40%
12,235.00
Operating Income
3,952.00
+17.48%
3,364.00
+5.32%
3,194.00
+18.74%
2,690.00
Total Operating Income As Reported
2,157.00
+811.88%
-303.00
-169.98%
433.00
+119.71%
-2,197.00
EBITDA
3,141.00
+304.25%
777.00
-50.13%
1,558.00
+268.43%
-925.00
Normalized EBITDA
4,884.00
+11.41%
4,384.00
+2.62%
4,272.00
+9.31%
3,908.00
Reconciled Depreciation
1,002.00
-5.38%
1,059.00
-8.15%
1,153.00
-11.85%
1,308.00
EBIT
2,139.00
+858.51%
-282.00
-169.63%
405.00
+118.14%
-2,233.00
Total Unusual Items
-1,743.00
+51.68%
-3,607.00
-32.90%
-2,714.00
+43.84%
-4,833.00
Total Unusual Items Excluding Goodwill
-1,743.00
+51.68%
-3,607.00
-32.90%
-2,714.00
+43.84%
-4,833.00
Special Income Charges
-1,794.00
+51.20%
-3,676.00
-33.58%
-2,752.00
+43.36%
-4,859.00
Other Special Charges
467.00
-38.63%
761.00
-27.04%
1,043.00
-49.59%
2,069.00
Impairment Of Capital Assets
1,028.00
-59.77%
2,555.00
+137.01%
1,078.00
-55.95%
2,447.00
Restructuring And Mergern Acquisition
279.00
-25.99%
377.00
-42.79%
659.00
+61.92%
407.00
Net Income
1,410.00
+186.03%
-1,639.00
-193.20%
-559.00
+77.15%
-2,446.00
Pretax Income
1,223.00
+195.25%
-1,284.00
-105.77%
-624.00
+80.27%
-3,163.00
Net Non Operating Interest Income Expense
-985.00
+6.19%
-1,050.00
+4.11%
-1,095.00
-10.49%
-991.00
Interest Expense Non Operating
916.00
-8.58%
1,002.00
-2.62%
1,029.00
+10.65%
930.00
Net Interest Income
-985.00
+6.19%
-1,050.00
+4.11%
-1,095.00
-10.49%
-991.00
Interest Expense
916.00
-8.58%
1,002.00
-2.62%
1,029.00
+10.65%
930.00
Other Income Expense
-1,742.00
+51.57%
-3,597.00
-32.10%
-2,723.00
+43.96%
-4,859.00
Other Non Operating Income Expenses
1.00
-90.00%
10.00
+211.11%
-9.00
+65.38%
-26.00
Gain On Sale Of Security
51.00
-26.09%
69.00
+81.58%
38.00
+46.15%
26.00
Gain On Sale Of Business
-22.00
-246.67%
15.00
+400.00%
3.00
-93.48%
46.00
Tax Provision
-180.00
-126.63%
676.00
+9757.14%
-7.00
+98.91%
-643.00
Tax Rate For Calcs
0.00
+0.00%
0.00
+2200.00%
0.00
-95.00%
0.00
Tax Effect Of Unusual Items
-400.89
+51.68%
-829.61
-2956.78%
-27.14
+97.19%
-966.60
Net Income Including Noncontrolling Interests
1,418.00
+172.38%
-1,959.00
-218.54%
-615.00
+75.39%
-2,499.00
Net Income From Continuing Operation Net Minority Interest
1,410.00
+186.03%
-1,639.00
-193.20%
-559.00
+77.15%
-2,446.00
Net Income From Continuing And Discontinued Operation
1,410.00
+186.03%
-1,639.00
-193.20%
-559.00
+77.15%
-2,446.00
Net Income Continuous Operations
1,418.00
+172.38%
-1,959.00
-218.54%
-615.00
+75.39%
-2,499.00
Minority Interests
-7.00
-102.19%
320.00
+471.43%
56.00
+5.66%
53.00
Normalized Income
2,752.11
+141.75%
1,138.39
-46.50%
2,127.86
+49.81%
1,420.40
Net Income Common Stockholders
1,410.00
+186.03%
-1,639.00
-193.20%
-559.00
+77.15%
-2,446.00
Diluted EPS
1.21
+183.45%
-1.45
-190.00%
-0.50
+76.42%
-2.12
Basic EPS
1.23
+184.83%
-1.45
-190.00%
-0.50
+76.42%
-2.12
Basic Average Shares
1,145.00
+1.24%
1,131.00
+1.07%
1,119.00
+0.81%
1,110.00
Diluted Average Shares
1,163.00
+2.83%
1,131.00
+1.07%
1,119.00
+0.81%
1,110.00
Diluted NI Availto Com Stockholders
1,410.00
+186.03%
-1,639.00
-193.20%
-559.00
+77.15%
-2,446.00
Earnings From Equity Interest Net Of Tax
15.00
+1400.00%
1.00
-50.00%
2.00
-90.48%
21.00
Gain On Sale Of PPE
2.00
+0.00%
2.00
-92.00%
25.00
+38.89%
18.00
Total Other Finance Cost
69.00
+43.75%
48.00
-27.27%
66.00
+8.20%
61.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
40,748.00
+3.62%
39,326.00
-9.55%
43,479.00
-1.21%
44,011.00
Current Assets
13,946.00
+11.11%
12,552.00
+0.54%
12,485.00
+3.60%
12,051.00
Cash Cash Equivalents And Short Term Investments
3,556.00
+7.76%
3,300.00
+2.29%
3,226.00
+15.17%
2,801.00
Cash And Cash Equivalents
3,556.00
+7.76%
3,300.00
+2.29%
3,226.00
+15.17%
2,801.00
Cash Equivalents
2,678.00
+33.57%
2,005.00
+17.66%
1,704.00
+39.44%
1,222.00
Cash Financial
878.00
-32.20%
1,295.00
-14.91%
1,522.00
-3.61%
1,579.00
Receivables
3,709.00
+21.25%
3,059.00
-10.24%
3,408.00
-7.79%
3,696.00
Accounts Receivable
3,709.00
+21.25%
3,059.00
-10.24%
3,408.00
-7.79%
3,696.00
Gross Accounts Receivable
3,790.00
+20.82%
3,137.00
-10.45%
3,503.00
-7.50%
3,787.00
Allowance For Doubtful Accounts Receivable
-81.00
-3.85%
-78.00
+17.89%
-95.00
-4.40%
-91.00
Inventory
3,179.00
+5.72%
3,007.00
-25.22%
4,021.00
+4.90%
3,833.00
Raw Materials
911.00
+4.71%
870.00
-26.02%
1,176.00
-8.91%
1,291.00
Work In Process
364.00
+3.12%
353.00
-29.40%
500.00
-9.91%
555.00
Finished Goods
1,904.00
+6.79%
1,783.00
-24.00%
2,346.00
+18.07%
1,987.00
Prepaid Assets
1,122.00
+11.53%
1,006.00
-19.84%
1,255.00
+8.00%
1,162.00
Assets Held For Sale Current
1,842.00
+4.01%
1,771.00
+2430.00%
70.00
+600.00%
10.00
Other Current Assets
538.00
+31.54%
409.00
-19.01%
505.00
-8.01%
549.00
Total Non Current Assets
26,802.00
+0.10%
26,774.00
-13.61%
30,993.00
-3.03%
31,960.00
Net PPE
4,425.00
-10.57%
4,948.00
-19.51%
6,147.00
-0.18%
6,158.00
Gross PPE
9,153.00
-2.19%
9,358.00
-20.59%
11,784.00
+0.92%
11,676.00
Accumulated Depreciation
-4,728.00
-7.21%
-4,410.00
+21.77%
-5,637.00
-2.16%
-5,518.00
Properties
0.00
0.00
0.00
0.00
Land And Improvements
258.00
+21.13%
213.00
-13.41%
246.00
+0.00%
246.00
Buildings And Improvements
2,327.00
+18.24%
1,968.00
-20.90%
2,488.00
+1.02%
2,463.00
Machinery Furniture Equipment
5,846.00
+6.68%
5,480.00
-24.16%
7,226.00
-1.67%
7,349.00
Construction In Progress
377.00
-71.65%
1,330.00
-6.80%
1,427.00
+19.02%
1,199.00
Other Properties
345.00
-5.99%
367.00
-7.56%
397.00
-5.25%
419.00
Goodwill And Other Intangible Assets
19,781.00
+1.10%
19,565.00
-13.29%
22,564.00
-5.60%
23,903.00
Goodwill
16,000.00
+5.63%
15,147.00
-11.82%
17,177.00
-2.59%
17,633.00
Other Intangible Assets
3,781.00
-14.42%
4,418.00
-17.99%
5,387.00
-14.08%
6,270.00
Non Current Deferred Assets
2,191.00
+21.79%
1,799.00
-0.72%
1,812.00
+24.28%
1,458.00
Non Current Deferred Taxes Assets
2,191.00
+21.79%
1,799.00
-0.72%
1,812.00
+24.28%
1,458.00
Other Non Current Assets
405.00
-12.34%
462.00
-1.70%
470.00
+6.58%
441.00
Total Liabilities Net Minority Interest
32,834.00
-2.30%
33,606.00
-4.94%
35,353.00
-0.17%
35,413.00
Current Liabilities
13,456.00
+5.16%
12,796.00
+4.48%
12,247.00
+6.78%
11,469.00
Payables And Accrued Expenses
5,218.00
+4.46%
4,995.00
-7.04%
5,373.00
+33.06%
4,038.00
Payables
2,531.00
+14.89%
2,203.00
-15.33%
2,602.00
+37.89%
1,887.00
Accounts Payable
2,531.00
+14.89%
2,203.00
-15.33%
2,602.00
+37.89%
1,887.00
Current Accrued Expenses
2,687.00
-3.76%
2,792.00
+0.76%
2,771.00
+28.82%
2,151.00
Pensionand Other Post Retirement Benefit Plans Current
739.00
+18.43%
624.00
+2.13%
611.00
+7.95%
566.00
Current Debt And Capital Lease Obligation
1,820.00
+2.19%
1,781.00
+6.52%
1,672.00
-20.72%
2,109.00
Current Debt
1,820.00
+2.19%
1,781.00
+6.52%
1,672.00
-20.72%
2,109.00
Other Current Borrowings
1,820.00
+2.19%
1,781.00
+6.52%
1,672.00
-20.72%
2,109.00
Other Current Liabilities
1,536.00
-10.59%
1,718.00
+62.69%
1,056.00
+4.97%
1,006.00
Total Non Current Liabilities Net Minority Interest
19,378.00
-6.88%
20,810.00
-9.94%
23,106.00
-3.50%
23,944.00
Long Term Debt And Capital Lease Obligation
15,274.00
-6.28%
16,298.00
-11.81%
18,481.00
-4.99%
19,452.00
Long Term Debt
14,986.00
-6.35%
16,002.00
-11.89%
18,161.00
-4.93%
19,103.00
Long Term Capital Lease Obligation
288.00
-2.70%
296.00
-7.50%
320.00
-8.31%
349.00
Tradeand Other Payables Non Current
—
—
—
3,847.00
Non Current Deferred Liabilities
296.00
-38.72%
483.00
-20.30%
606.00
+10.58%
548.00
Non Current Deferred Taxes Liabilities
296.00
-38.72%
483.00
-20.30%
606.00
+10.58%
548.00
Other Non Current Liabilities
3,808.00
-5.49%
4,029.00
+0.25%
4,019.00
+1.90%
3,944.00
Stockholders Equity
7,910.00
+47.22%
5,373.00
-28.42%
7,506.00
-3.82%
7,804.00
Common Stock Equity
7,910.00
+47.22%
5,373.00
-28.42%
7,506.00
-3.82%
7,804.00
Capital Stock
58.00
+0.00%
58.00
+1.75%
57.00
+0.00%
57.00
Common Stock
58.00
+0.00%
58.00
+1.75%
57.00
+0.00%
57.00
Share Issued
1,256.37
+1.25%
1,240.84
+1.12%
1,227.09
+0.84%
1,216.90
Ordinary Shares Number
1,149.81
+1.41%
1,133.84
+1.14%
1,121.09
+0.92%
1,110.90
Treasury Shares Number
106.56
-0.42%
107.00
+0.94%
106.00
+0.00%
106.00
Additional Paid In Capital
28,133.00
+1.33%
27,764.00
-0.15%
27,807.00
+0.43%
27,688.00
Retained Earnings
-13,762.00
+9.30%
-15,173.00
-12.11%
-13,534.00
-4.31%
-12,975.00
Gains Losses Not Affecting Retained Earnings
-2,391.00
+24.05%
-3,148.00
-16.72%
-2,697.00
+4.97%
-2,838.00
Treasury Stock
4,128.00
+0.00%
4,128.00
+0.00%
4,128.00
+0.00%
4,128.00
Minority Interest
4.00
-98.85%
347.00
-44.03%
620.00
-21.91%
794.00
Other Equity Adjustments
-2,391.00
+24.05%
-3,148.00
-16.72%
-2,697.00
+4.97%
-2,838.00
Total Equity Gross Minority Interest
7,914.00
+38.36%
5,720.00
-29.61%
8,126.00
-5.49%
8,598.00
Total Capitalization
22,896.00
+7.12%
21,375.00
-16.72%
25,667.00
-4.61%
26,907.00
Working Capital
490.00
+300.82%
-244.00
-202.52%
238.00
-59.11%
582.00
Invested Capital
24,716.00
+6.74%
23,156.00
-15.30%
27,339.00
-5.78%
29,016.00
Total Debt
17,094.00
-5.45%
18,079.00
-10.29%
20,153.00
-6.53%
21,561.00
Net Debt
13,250.00
-8.51%
14,483.00
-12.79%
16,607.00
-9.80%
18,411.00
Capital Lease Obligations
288.00
-2.70%
296.00
-7.50%
320.00
-8.31%
349.00
Net Tangible Assets
-11,871.00
+16.35%
-14,192.00
+5.75%
-15,058.00
+6.47%
-16,099.00
Tangible Book Value
-11,871.00
+16.35%
-14,192.00
+5.75%
-15,058.00
+6.47%
-16,099.00
Current Provisions
4,143.00
+12.64%
3,678.00
+4.05%
3,535.00
-5.73%
3,750.00
Other Equity Interest
—
—
1.00
—
Other Inventories
—
1.00
+200.00%
-1.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
1,649.00
+32.24%
1,247.00
-8.85%
1,368.00
-13.96%
1,590.00
Cash Flow From Continuing Operating Activities
1,649.00
+32.24%
1,247.00
-8.85%
1,368.00
-13.96%
1,590.00
Net Income From Continuing Operations
1,418.00
+172.38%
-1,959.00
-218.54%
-615.00
+75.39%
-2,499.00
Depreciation Amortization Depletion
1,002.00
-5.38%
1,059.00
-8.15%
1,153.00
-11.85%
1,308.00
Depreciation
421.00
-10.62%
471.00
-12.29%
537.00
-6.77%
576.00
Amortization Cash Flow
581.00
-1.19%
588.00
-4.55%
616.00
-15.85%
732.00
Depreciation And Amortization
1,002.00
-5.38%
1,059.00
-8.15%
1,153.00
-11.85%
1,308.00
Amortization Of Intangibles
581.00
-1.19%
588.00
-4.55%
616.00
-15.85%
732.00
Other Non Cash Items
81.00
-85.54%
560.00
+818.03%
61.00
+167.03%
-91.00
Stock Based Compensation
157.00
+27.64%
123.00
+1.65%
121.00
-2.42%
124.00
Asset Impairment Charge
1,028.00
-59.77%
2,555.00
+137.01%
1,078.00
-55.95%
2,447.00
Deferred Tax
-671.00
-5.84%
-634.00
-100.00%
-317.00
+70.21%
-1,064.00
Deferred Income Tax
-671.00
-5.84%
-634.00
-100.00%
-317.00
+70.21%
-1,064.00
Operating Gains Losses
—
-22.00
+46.34%
-41.00
-510.00%
10.00
Gain Loss On Investment Securities
—
—
-41.00
-510.00%
10.00
Gain Loss On Sale Of PPE
—
—
—
10.00
Change In Working Capital
-1,366.00
-214.02%
-435.00
-504.17%
-72.00
-105.31%
1,355.00
Change In Receivables
-173.00
-170.61%
245.00
+1941.67%
12.00
-96.41%
334.00
Changes In Account Receivables
-173.00
-170.61%
245.00
+1941.67%
12.00
-96.41%
334.00
Change In Inventory
152.00
-8.43%
166.00
+212.93%
-147.00
+9.82%
-163.00
Change In Payables And Accrued Expense
-15.00
-105.81%
258.00
-83.75%
1,588.00
-21.07%
2,012.00
Change In Payable
-15.00
-105.81%
258.00
-83.75%
1,588.00
-21.07%
2,012.00
Change In Account Payable
-15.00
-105.81%
258.00
-83.75%
1,588.00
-21.07%
2,012.00
Change In Other Current Assets
-1,330.00
-20.47%
-1,104.00
+27.61%
-1,525.00
-84.18%
-828.00
Investing Cash Flow
737.00
-6.94%
792.00
-18.18%
968.00
+47.56%
656.00
Cash Flow From Continuing Investing Activities
737.00
-6.94%
792.00
-18.18%
968.00
+47.56%
656.00
Net PPE Purchase And Sale
-501.00
-0.60%
-498.00
+5.32%
-526.00
+4.01%
-548.00
Purchase Of PPE
-501.00
-0.60%
-498.00
+5.32%
-526.00
+4.01%
-548.00
Sale Of PPE
—
—
—
—
Capital Expenditure
-501.00
-0.60%
-498.00
+5.32%
-526.00
+4.01%
-548.00
Net Investment Purchase And Sale
-15.00
+51.61%
-31.00
+32.61%
-46.00
-1633.33%
3.00
Purchase Of Investment
-57.00
+19.72%
-71.00
-54.35%
-46.00
-4500.00%
-1.00
Sale Of Investment
42.00
+5.00%
40.00
0.00
-100.00%
4.00
Net Business Purchase And Sale
34.00
+21.43%
28.00
-58.82%
68.00
+11.48%
61.00
Purchase Of Business
0.00
+100.00%
-15.00
0.00
+100.00%
-7.00
Gain Loss On Sale Of Business
0.00
+100.00%
-22.00
+46.34%
-41.00
-510.00%
10.00
Net Other Investing Changes
5.00
+150.00%
2.00
+140.00%
-5.00
—
Financing Cash Flow
-2,151.00
-20.10%
-1,791.00
+6.38%
-1,913.00
-28.65%
-1,487.00
Cash Flow From Continuing Financing Activities
-2,151.00
-20.10%
-1,791.00
+6.38%
-1,913.00
-28.65%
-1,487.00
Net Issuance Payments Of Debt
-1,814.00
-10.54%
-1,641.00
+3.53%
-1,701.00
-24.25%
-1,369.00
Issuance Of Debt
2,298.00
0.00
-100.00%
3,151.00
0.00
Repayment Of Debt
-4,112.00
-150.58%
-1,641.00
+66.18%
-4,852.00
-254.42%
-1,369.00
Long Term Debt Issuance
2,298.00
0.00
-100.00%
2,451.00
0.00
Long Term Debt Payments
-4,112.00
-150.58%
-1,641.00
+60.48%
-4,152.00
-203.29%
-1,369.00
Net Long Term Debt Issuance
-1,814.00
-10.54%
-1,641.00
+3.53%
-1,701.00
-24.25%
-1,369.00
Short Term Debt Issuance
0.00
0.00
-100.00%
700.00
0.00
Short Term Debt Payments
0.00
0.00
+100.00%
-700.00
0.00
Net Short Term Debt Issuance
0.00
0.00
0.00
0.00
Net Other Financing Charges
-337.00
-124.67%
-150.00
+29.25%
-212.00
-79.66%
-118.00
Changes In Cash
235.00
-4.86%
247.00
-41.61%
423.00
-44.27%
759.00
Effect Of Exchange Rate Changes
21.00
+112.07%
-174.00
-480.00%
-30.00
+75.61%
-123.00
Beginning Cash Position
3,300.00
+2.26%
3,227.00
+13.87%
2,834.00
+28.94%
2,198.00
End Cash Position
3,556.00
+7.76%
3,300.00
+2.26%
3,227.00
+13.87%
2,834.00
Free Cash Flow
1,148.00
+53.27%
749.00
-11.05%
842.00
-19.19%
1,042.00
Interest Paid Supplemental Data
950.00
-5.38%
1,004.00
-6.86%
1,078.00
+13.71%
948.00
Income Tax Paid Supplemental Data
—
471.00
+58.05%
298.00
-45.12%
543.00
Interest Received CFI
1,214.00
-5.96%
1,291.00
-12.59%
1,477.00
+29.56%
1,140.00
Sale Of Business
34.00
-20.93%
43.00
-36.76%
68.00
+0.00%
68.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category